The body has a natural mechanism for breaking down and clearing proteins. Arvinas is among a group of companies that’s seeking to harness this mechanism for therapeutic purposes. It has platform technology that enables the development of targeted protein degraders to breakdown disease-causing proteins. Among the benefits of this approach is that it offers a way to target so-called undruggable proteins that conventional drugs are not able to bind with in a strong enough way. We spoke to Randy Teel, chief business officer and interim chief financial officer of Arvinas, about protein degradation, its evolution as a therapeutic strategy, and the range of indications the company is pursuing.
.png)
More
Religion & Spirituality
Education
Arts and Design
Health
Fashion & Beauty
Government & Organizations
Kids & family
Music
News & Politics
Science & Medicine
Society & Culture
Sports & Recreation
TV & Film
Technology
Philosophy
Storytelling
Horror and Paranomal
True Crime
Leisure
Travel
Fiction
Crypto
Marketing
History
Comedy
Arts
Games & Hobbies
Business
Motivation